Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

4basebio

DB:EXNN
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EXNN
DB
€85M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

4basebio AG, an enabler of advances in medical science and patient care, focuses on manufacturing DNA products for therapeutic and other uses. The last earnings update was 151 days ago. More info.


Add to Portfolio Compare Print
EXNN Share Price and Events
7 Day Returns
3.9%
DB:EXNN
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
85.1%
DB:EXNN
-13.5%
DE Biotechs
-20.9%
DE Market
EXNN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
4basebio (EXNN) 3.9% -3.6% -5.8% 85.1% 7% -66.4%
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • EXNN outperformed the Biotechs industry which returned -13.5% over the past year.
  • EXNN outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
EXNN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is 4basebio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of 4basebio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for 4basebio.

DB:EXNN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:EXNN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 30%) (10.57%))
1.185
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.18
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.185 * 5.44%)
6.06%

Discounted Cash Flow Calculation for DB:EXNN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for 4basebio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:EXNN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.06%)
2020 0.04 Analyst x1 0.04
2021 2.00 Analyst x1 1.78
2022 3.79 Est @ 89.69% 3.18
2023 6.17 Est @ 62.67% 4.87
2024 8.86 Est @ 43.75% 6.61
2025 11.57 Est @ 30.51% 8.13
2026 14.02 Est @ 21.24% 9.29
2027 16.09 Est @ 14.75% 10.05
2028 17.73 Est @ 10.21% 10.45
2029 18.98 Est @ 7.03% 10.54
Present value of next 10 years cash flows €64.00
DB:EXNN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €18.98 × (1 + -0.39%) ÷ (6.06% – -0.39%)
€293.35
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €293.35 ÷ (1 + 6.06%)10
€162.95
DB:EXNN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €64.00 + €162.95
€226.95
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €226.95 / 53.03
€4.28
DB:EXNN Discount to Share Price
Calculation Result
Value per share (EUR) From above. €4.28
Current discount Discount to share price of €1.61
= -1 x (€1.61 - €4.28) / €4.28
62.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price 4basebio is available for.
Intrinsic value
>50%
Share price is €1.61 vs Future cash flow value of €4.28
Current Discount Checks
For 4basebio to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • 4basebio's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • 4basebio's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for 4basebio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are 4basebio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:EXNN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in EUR €-0.02
XTRA:EXNN Share Price ** XTRA (2020-04-03) in EUR €1.61
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of 4basebio.

DB:EXNN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:EXNN Share Price ÷ EPS (both in EUR)

= 1.61 ÷ -0.02

-94.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4basebio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • 4basebio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does 4basebio's expected growth come at a high price?
Raw Data
DB:EXNN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -94.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
124.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for 4basebio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on 4basebio's assets?
Raw Data
DB:EXNN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in EUR €1.02
XTRA:EXNN Share Price * XTRA (2020-04-03) in EUR €1.61
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:EXNN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:EXNN Share Price ÷ Book Value per Share (both in EUR)

= 1.61 ÷ 1.02

1.59x

* Primary Listing of 4basebio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • 4basebio is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess 4basebio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. 4basebio has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is 4basebio expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
124.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is 4basebio expected to grow at an attractive rate?
  • 4basebio's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • 4basebio's earnings growth is expected to exceed the Germany market average.
  • 4basebio's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:EXNN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:EXNN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 124.2%
DB:EXNN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 18.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:EXNN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:EXNN Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 40 1
2023-12-31 33 1
2022-12-31 28 1
2021-12-31 23 3 2 1
2020-12-31 19 1 0 1
2020-04-06
2019-12-31 16 1 -2 2
DB:EXNN Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-09-30 15 1 -1
2019-06-30 15 0 -1
2019-03-31 14 0 0
2018-12-31 13 0 0
2018-09-30 12 -1 -2
2018-06-30 10 -2 -3
2018-03-31 9 -2 -3
2017-12-31 8 -3 -4
2017-09-30 6 -4 -5
2017-06-30 4 -3 -5
2017-03-31 3 -3 -5
2016-12-31 2 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • 4basebio's earnings are expected to grow significantly at over 20% yearly.
  • 4basebio's revenue is expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:EXNN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from 4basebio Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EXNN Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.03 0.03 0.03 1.00
2020-12-31 0.00 0.00 0.00 1.00
2020-04-06
2019-12-31 -0.01 -0.01 -0.01 1.00
DB:EXNN Past Financials Data
Date (Data in EUR Millions) EPS *
2019-09-30 -0.02
2019-06-30 -0.02
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.04
2018-06-30 -0.05
2018-03-31 -0.07
2017-12-31 -0.09
2017-09-30 -0.14
2017-06-30 -0.15
2017-03-31 -0.18
2016-12-31 -0.20

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • 4basebio is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess 4basebio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
4basebio has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has 4basebio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare 4basebio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • 4basebio does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare 4basebio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare 4basebio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
4basebio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from 4basebio Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EXNN Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 15.30 -0.90 11.07 1.65
2019-06-30 14.86 -1.21 11.80 1.29
2019-03-31 14.27 -0.44 10.96 1.26
2018-12-31 13.13 -0.30 10.22 1.04
2018-09-30 11.74 -1.95 10.28 0.74
2018-06-30 10.44 -2.59 9.77 0.99
2018-03-31 8.74 -2.82 8.72 0.83
2017-12-31 7.80 -3.70 8.48 0.79
2017-09-30 6.15 -5.39 7.50 0.82
2017-06-30 4.45 -4.92 5.66 0.87
2017-03-31 3.07 -4.91 4.53 1.08
2016-12-31 1.79 -4.39 3.43 1.22
2016-09-30 1.22 -3.38 2.69 1.21
2016-06-30 0.68 -3.55 2.51 1.28
2016-03-31 0.57 -3.95 2.59 1.42
2015-12-31 0.56 -4.01 2.64 1.41
2015-09-30 0.40 -3.89 2.24 1.48
2015-06-30 0.43 -3.81 2.20 1.43
2015-03-31 0.40 -3.38 1.96 1.32
2014-12-31 0.39 -3.48 1.94 1.41
2014-09-30 0.37 -2.72 2.03 1.63
2014-06-30 0.32 -2.75 1.94 1.68
2014-03-31 0.50 -2.82 1.95 1.89
2013-12-31 0.48 -3.20 2.13 2.23
2013-09-30 0.43 -3.39 1.83 2.13
2013-06-30 0.53 -3.57 1.49 1.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if 4basebio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if 4basebio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if 4basebio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess 4basebio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
4basebio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is 4basebio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up 4basebio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • 4basebio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • 4basebio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of 4basebio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from 4basebio Company Filings, last reported 6 months ago.

DB:EXNN Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 46.99 9.03 3.29
2019-06-30 46.34 8.46 3.86
2019-03-31 47.17 10.76 5.64
2018-12-31 46.50 10.65 6.24
2018-09-30 44.20 14.35 4.24
2018-06-30 43.81 10.73 1.07
2018-03-31 43.64 5.45 5.05
2017-12-31 39.07 5.71 1.95
2017-09-30 39.95 5.18 1.49
2017-06-30 41.41 2.96 2.68
2017-03-31 30.65 2.45 2.05
2016-12-31 31.41 2.71 3.80
2016-09-30 29.75 2.56 4.59
2016-06-30 8.59 2.09 2.41
2016-03-31 9.72 2.11 3.37
2015-12-31 10.41 2.12 4.56
2015-09-30 5.97 2.94 0.61
2015-06-30 6.51 2.93 1.28
2015-03-31 7.57 2.91 2.52
2014-12-31 8.34 3.03 3.76
2014-09-30 4.83 2.91 0.36
2014-06-30 5.43 2.83 0.80
2014-03-31 5.74 2.80 1.19
2013-12-31 5.95 3.58 2.20
2013-09-30 3.51 2.81 0.08
2013-06-30 4.31 2.23 0.23
  • 4basebio's level of debt (18.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (59.8% vs 18.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making 4basebio has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making 4basebio has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -13.1% per year.
X
Financial health checks
We assess 4basebio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. 4basebio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is 4basebio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from 4basebio dividends.
If you bought €2,000 of 4basebio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate 4basebio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate 4basebio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:EXNN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:EXNN Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as 4basebio has not reported any payouts.
  • Unable to verify if 4basebio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of 4basebio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as 4basebio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess 4basebio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can 4basebio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. 4basebio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of 4basebio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Heikki Lanckriet
COMPENSATION €196,000
TENURE AS CEO 2.8 years
CEO Bio

Dr. Heikki Lanckriet, Ph.D. has been Chief Executive Officer of Sygnis AG since July 7, 2017, Chief Scientific Officer since August 5, 2016 and also serves as its Member of Management Board. Dr. Lanckriet served as Co-Chief Executive Officer at Sygnis AG from August 5, 2016 to July 7, 2017. Dr. Lanckriet co-founded Expedeon Ltd. (alternative name Novexin Ltd. and Expedeon Holdings Ltd.) in 2003. Dr. Lanckriet serves as Chief Executive Officer, Director of Operations/Chief Operating Officer and Founding Scientist/CSO at Novexin Ltd. He has accumulating a deep knowledge of the life sciences tools and reagents business. He served as Research Manager at enzyme company Puratos NV and as a Researcher in protein processing at University of Cambridge. He served as a Director of Expedeon Ltd. He has published papers in peer-reviewed international scientific journals and is named inventor on a number of patents. Dr. Lanckriet holds a bachelor's and master's degree in biochemical engineering from the University of Ghent, Belgium and a PhD in biochemical engineering from the University of Cambridge, UK.

CEO Compensation
  • Heikki's compensation has increased whilst company is loss making.
  • Heikki's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the 4basebio management team in years:

3.1
Average Tenure
  • The tenure for the 4basebio management team is about average.
Management Team

Heikki Lanckriet

TITLE
CEO, Chief Scientific Officer & Member of Management Board
COMPENSATION
€196K
TENURE
2.8 yrs

David Roth

TITLE
CFO & Member of Management Board
COMPENSATION
€188K
TENURE
3.1 yrs

Nick Gee

TITLE
Chief Technical Officer
TENURE
2.8 yrs

Sebastian Paul

TITLE
Vice President of Finance and Administration
TENURE
4.8 yrs

Antonio Gómez-Almansa

TITLE
General Counsel

Miguel-Antonio Viribay

TITLE
Vice President of Sales & Marketing
TENURE
5 yrs

Margarita Salas

TITLE
Board of Directors Tenure

Average tenure of the 4basebio board of directors in years:

2.8
Average Tenure
  • The average tenure for the 4basebio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Joe Fernandez

TITLE
Chairman of Supervisory Board
COMPENSATION
€30K
TENURE
1 yrs

Peter Llewellyn-Davies

TITLE
Member of Supervisory Board
COMPENSATION
€30K
TENURE
2.8 yrs

María del de la Huerta

TITLE
Member of Supervisory Board
COMPENSATION
€20K
TENURE
2.8 yrs

Luis Dávila

TITLE

Margarita Salas

TITLE

Tim McCarthy

TITLE
Member of Supervisory Board
COMPENSATION
€20K
AGE
62
TENURE
3.8 yrs

Trevor Jarman

TITLE
Member of Supervisory Board
COMPENSATION
€20K
TENURE
3.8 yrs

Hansjörg Plaggemars

TITLE
Member of Supervisory Board
AGE
49
TENURE
0.8 yrs

Santiago Mas

TITLE
Substitute Membe of Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess 4basebio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. 4basebio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

4basebio AG, an enabler of advances in medical science and patient care, focuses on manufacturing DNA products for therapeutic and other uses. It also focuses on providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase, and DNA primase enzymes, addressing the research tools and diagnostic products markets. Its technologies, products, and services have applications in point-of-care and clinical diagnostics and are used in research laboratories worldwide. The company was formerly known as Expedeon AG and changed its name to 4basebio AG in January 2020. 4basebio AG is based in Heidelberg, Germany.

Details
Name: 4basebio AG
EXNN
Exchange: DB
Founded:
€85,383,414
53,033,177
Website: http://www.4basebio.com
Address: 4basebio AG
Waldhofer Str. 104,
Heidelberg,
Baden-Württemberg, 69123,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA EXNN Registered Shares XETRA Trading Platform DE EUR 06. Dec 2012
DB EXNN Registered Shares Deutsche Boerse AG DE EUR 06. Dec 2012
Number of employees
Current staff
Staff numbers
103
4basebio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 05:34
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/04
Last earnings filing: 2019/11/07
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.